Presentation - James E. Polli University of Maryland
- Background
- Prior human in vivo studies
- Recent series of in vivo human studies of 14 common excipients
- Potential transporter (or enzyme or nuclear receptor) x excipient interaction concern
- Conclusions
BCS Class 3 Biowaivers and Transporter Considerations